Yahoo Finance Is Abbott Laboratories (NYSE:ABT) the Best Value Dividend Aristocrat Stock?
We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since Abbott Laboratories (NYSE:ABT) ranks higher on our list, we have analyzed the stock in detail.
The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently the favored option in the market as investors seek out strategies to grow their income over time. In this regard, investors turn to dividend aristocrats, which are the companies that have raised their payouts for 25 consecutive years or more. These stocks have delivered strong returns over the years regardless of market conditions. Between February 2005 and December 2023, dividend aristocrats delivered a 12.50% return in falling interest rate periods and an 11.5% return in rising interest rate periods, according to data by Bloomberg.
Numerous analysts have pointed out the long-term potential of dividend growth stocks, a sentiment echoed by Warren Buffett’s investment in Coca-Cola. Back in August 1994, Berkshire Hathaway completed its acquisition of 400 million shares in the company, worth $1.3 billion. Berkshire initially received a cash dividend of $75 million from Coca-Cola in 1994, the amount which surged to $704 million in 2022. This shows a remarkable growth potential of dividend-paying investments over the long term.
With investors showing a growing preference for dividend-paying stocks, major tech companies started initiating their dividend policies this year. Mark Iong, an equity fund manager at Homestead Advisers, expressed his approval of this move by tech companies in one of his recent interviews with Bloomberg. Here are some comments from the analyst:
“Dividends will be table-stakes for big tech going forward. I think if you don’t pay one, it will now be taken as a sign your business is more volatile. What’s exciting is they are doing dividends and buybacks simultaneously, while also cutting costs and growing, which is them stepping on the pedal for profits across the board.”
Not limited to the tech sector alone, companies across the broader market are showing a strong commitment to dividends this year. Though these equities lagged behind the market last year, their outlook remains strong this year. According to a recent report by S&P Dow Jones Indices, in the first quarter of 2024, companies in the index paid $151.6 billion in dividends, up from $146.8 billion paid during the same period last year. In addition, 796 companies reported dividend hikes during the quarter, amounting collectively to $22.7 billion. Howard Silverblatt, Senior Index Analyst at S&P Dow Jones Indices, expects that the index will report a 6% year-over-year increase in dividend payments in 2024.
Now, let’s take a look at some of the best dividend aristocrat stocks to buy according to analysts.
Photo by Sharon McCutcheon on Unsplash
Our Methodology:
For our list, we first scanned a list of the best dividend aristocrat stocks, which are the companies that have raised their dividends for 25 consecutive years or more. From this group, we picked stocks with a projected upside potential of over 10% based on analyst price targets. The stocks are ranked according to their upside potential, as of May 26. We also measured hedge fund sentiment around each stock according to Insider Monkey’s database of 920 funds as of Q1 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
Abbott Laboratories (NYSE:ABT)
Upside Potential as of May 26: 22.8%
Abbott Laboratories (NYSE:ABT) is a global healthcare company that offers a wide range of related products and services to its consumers. The company has been paying regular dividends to shareholders for 401 consecutive quarters and has raised its payouts for 52 years straight. It currently pays a per-share dividend of $0.51 every quarter and has a dividend yield of 2.12%, as of May 26.
Abbott Laboratories (NYSE:ABT) specializes in a wide range of products and services which reduces its dependency on any single market and helps it to generate revenue from multiple channels. The stock is up by over 2% in the past 12 months, as of the close of May 24. The stock has fallen from its high of around $120 per share earlier this year and is now trading at $101 per share, so it may present a potential buying opportunity for investors looking to capitalize on the lower price. Moreover, it has a forward P/E of 21.69, which is well below the industry average. In the first quarter of 2024, the company reported its fifth consecutive quarter of reporting double-digit organic sales growth in its underlying base business.
Polen Capital gave a positive outlook on Abbott Laboratories (NYSE:ABT) in its Q1 2024 investor letter. Here is what the firm has to say:
“We increased our positions in ThermoFisher Scientific, Visa, Zoetis, Nike, and Abbott Laboratories (NYSE:ABT). Each of these companies is durable and available at attractive valuations, in our view, for the growth we see ahead. In fact, in the case of ThermoFisher, Nike, and Abbott Labs, we expect accelerating earnings growth in the back half of 2024 after more difficult earnings growth periods pass for each of these companies. ThermoFisher and Abbott will finally wind down most of their COVID-19 testing and vaccine-related efforts due to a lack of demand, so these should no longer be revenue growth headwinds.”
We agree with Polen Capital and like the stock because of its undervaluation, dividend policy, and promising growth prospects.
Insider Monkey's database of Q1 2024 indicated that 62 hedge funds owned stakes in Abbott Laboratories (NYSE:ABT), down from 64 in the previous quarter. These stakes are worth nearly $2.7 billion in total. With over 10 million shares, Fisher Asset Management was the company's leading stakeholder in Q1.
Overall ABT ranks 4th among the best dividend aristocrat stocks according to analysts. You can visit 25 Best Dividend Aristocrats Stocks According to Analysts to see other dividend aristocrats that are on analysts’ radar. While we acknowledge the potential of dividend growth stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as Microsoft but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
Read Next: Michael Burry Is Selling These Stocks and Jim Cramer is Recommending These Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
